Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to site content Skip directly to page options
CDC Home

Laboratory Guidance Overview

Microscopic examination of tissue from patients with clinical cases of meningitis show evidence of pus, inflammation of blood vessels, dying tissue, and blood clots.

Microscopic examination of tissue from patients with clinical cases of meningitis show evidence of pus, inflammation of blood vessels, dying tissue, and blood clots.

Information on this site is focused on important laboratory findings and guidance related to the outbreak of fungal meningitis and other infections linked to the use of injectable steroids from three recalled lots of preservative-free methylprednisolone acetate (MPA) distributed by the New England Compounding Center (NECC).

For more information on the outbreak, see the Multistate Fungal Meningitis Outbreak Current Situation page. For information about laboratory results on NECC medications other than three lots of preservative-free MPA, see Information about Additional Medical Products (non-MPA) From New England Compounding Center.

Background

  • Three laboratories at CDC are working in coordination with state public health departments and clinicians to find out more about fungal infections in patients exposed to three lots of recalled preservative-free MPA.
  • Several laboratory experts and offices are working together on reviewing laboratory findings. All of these laboratories use a number of sophisticated testing methods including electron microscopy, polymerase chain reaction (PCR) amplification and sequencing of DNA, and MALDI-TOF mass spectrometry analysis.
    • The Mycotic Diseases Branch Fungus Reference Laboratory is conducting tests to detect fungal agents in CSF, joint fluid, and tissues from patients, and is confirming the identification of fungi isolated from patient specimens.
    • The Infectious Diseases Pathology Branch laboratory is examining tissues from biopsy and autopsy materials to confirm the presence of fungi and to document the pathology in human tissues.
    • The Clinical and Environmental Microbiology Branch laboratory has conducted sterility testing on various products from the NECC and Ameridose pharmacies.
  • Little information is known about the disease and pathogenesis caused by Exserohilum, the predominant pathogen associated with this outbreak.

Top of Page

A plate shows results of susceptibility testing to the antifungal drug amphotericin B.

During the multistate meningitis outbreak, a plate shows results of susceptibility testing to the antifungal drug amphotericin B. The drug inhibits growth of Exserohilum in the clear area where the amphotericin drug has diffused into the medium. Exserohilum is growing elsewhere on the plate.

Testing and Results

Pathologic Evaluation

Pathologic Results

FDA Updates

Publications and Resources

CDC Morbidity and Mortality Weekly Report (MMWR)

CDC Resources

Select Publications

U.S. Food and Drug Administration (FDA)

Top of Page

 
Contact Us:
  • Centers for Disease Control and Prevention
    1600 Clifton Rd
    Atlanta, GA 30333
  • 800-CDC-INFO
    (800-232-4636)
    TTY: (888) 232-6348
  • Contact CDC–INFO
USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO
A-Z Index
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
  27. #